Ennature Bio Pharma ne NSE aur BSE par entry maar li hai! Company ne FY26 mein **₹246 Crore** ka revenue aur **₹29 Crore** ka EBITDA report kiya hai, jo inke solid business model ko dikhata hai.
Market mein hui nayi entry
Ennature Bio Pharma ne finally apni listing complete kar li hai! November 4, 2026 ko company NSE aur BSE par live ho gayi hai. Ye listing unke future expansion plans aur pharma-nutraceutical space mein growth ke liye capital dene wali hai.
Financials par nazar
Company ne FY26 ke liye majboot data share kiya hai:
- Net Revenue: ₹246 Crore
- EBITDA: ₹29 Crore
- Gross Margin: 40.1%
15 saal ka experience aur 26 desh mein exports inke API division ko kafi strong banata hai, jo inki total sales ka 67% hai.
Business model mein kya hai khaas?
Company ke paas 3 main verticals hain:
- API (67%): Inka main revenue engine.
- Biopolymer (16%): Guar gum based business.
- Nutraceuticals (17%): Yahan company 'Aspargize', 'Gingeren' aur 'Maxicuma' jaise brands par focus kar rahi hai.
R&D aur Manufacturing power
Dehradun aur Kashipur mein inke manufacturing units hain, jahan EU-GMP aur USFDA jaise global standards maintain kiye jaate hain. Saath hi, 9 patents aur 20 clinical trials inki science-backed approach ko prove karte hain.
Investors ke liye caution
Company abhi generic botanical extracts se branded ingredients ki taraf move kar rahi hai. Iska matlab hai ki execution aur international markets mein distribution scale karna agle kuch quarters mein sabse bada test hoga. Naye API launches aur branded products ke expansion par nazar rakhein.